Cited by 265Metabolism and Genetic DisordersAmino Acid Enzymes and MetabolismNeonatal Health and Biochemistry

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Holme, E., Lindstedt, S.·1998·Journal of Inherited Metabolic Disease

DOI 10.1023/a:1005410820201

Open this paper in CoChat — free account

Abstract

In tyrosinaemia type I (McKusick 276700), fatal liver disease results either because of liver failure during infancy or early childhood or because of development of hepatocellular carcinoma during childhood or adolescence. This is caused by toxic metabolites which accumulate because of deficiency of fumarylacetoacetase, the last enzyme in the tyrosine catabolic pathway. NTBC is a potent inhibitor of 4‐hydroxyphenylpyruvate dioxygenase and has been shown to efficiently prevent tyrosine degradation, and production of succinylacetone, in patients with tyrosinaemia. Since the first trial of NTBC treatment for tyrosinaemia type I in 1991, over 220 patients have been treated by the drug using a protocol which includes regular follow‐up with reports of clinical and laboratory investigations to the study centre in Gothenburg, where additional analysis of critical variables is done on regularly collected samples. The course of the disease in patients with acute tyrosinaemia has changed dramatically. Only 10% of the patients have not clinically responded to NTBC treatment. In half of these patients, successful liver transplantation has been performed which has further reduced the mortality rate during infancy to 5%. The international NTBC study has now been going for 5 years and data have emerged that indicate a decreased risk for early development of hepatocellular carcinoma in patients who started treatment at an early age. There are now 101 patients aged 2–8 years who have started NTBC treatment before 2 years of age, and no cancer has developed after 2 years of age among these patients. However, there is no safe age with respect to occurrence of liver cancer, which has been recognized at diagnosis at 1 year of age in one patient and after a few months of treatment in an infant who was given NTBC at 5 months of age.

Integrity signals

Registry

Crossref · 10.1023/a:1005410820201

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631
Self-citation
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447
Self-citation
Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I
Grompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312
Self-citation
The occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Neurologic Crises in Hereditary Tyrosinemia
Mitchell, G. A., Larochelle, J., Lambert, M. A., Michaud, J., Grenier, A., de Baulny, H. O., Gauthier, M., Lacroix, J., Vanasse, M., Larbrisseau, A., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220704 · Cited by 230
Hereditary Tyrosinemia Type I: A New Clinical Classification With Difference in Prognosis on Dietary Treatment
Van Spronsen, F. J., Thomasse, Y., Smit, P. G. A., Leonard, J. V., Clayton, P. T., Fidler, V., Berger, R., & Heymans, H. S. A. (1994) · Hepatology · doi:10.1002/hep.1840200513 · Cited by 193
Self-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione
Ellis, M. K., Whitfield, A. C., Gowans, L. A., Auton, T. R., Provan, W. M., Lock, E. A., & Smith, L. L. (1995) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1995.1121 · Cited by 114
From toxicological problem to therapeutic use: The discovery of the mode of action of 2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione (NTBC), its toxicology and development as a drug
Lock, E. A., Ellis, M. K., Gaskin, P., Robinson, M., Auton, T. R., Provan, W. M., Smith, L. L., Prisbylla, M. P., Mutter, L. C., & Lee, D. L. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005458703363 · Cited by 109
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 2×
“In older patients, the low production may in part be due to self-induced correction of the fumarylacetoacetase defect (Kvittingen et al 1993, 1994), which has been documented to occur in nodules of regenerative liver tissue.”
Background

Flagged first, then by citations

Show all 17 references

Research works printed but not linked: 5

Dionisi‐Vici C, 1997, Tyrosinemia type I with early metastatic hepatocellular carcinoma: combined treatment with NTBC, chemotherapy and surgical mass removal, J Inher Metab Dis, 20, 15
Holme E, 1995, Treatment of tyrosinemia type I with an enzyme inhibitor, Int Pediatr, 10, 41
Kerckaert I, 1997, Secondary alterations of hepatic peroxisomes in tyrosinaemia type I: morphometry and electron microscopy, J Inher Metab Dis, 20, 13
Segel I, 1975, Enzyme Kinetics
Vilaseca MA, 1997, Chronic form of tyrosinaemia type I: late‐onset treatment with NTBC, J Inher Metab Dis, 20, 10

Sorted by citations

AASLD practice guidelines
Murray, K. F., & Carithers, R. L. (2005) · Hepatology · doi:10.1002/hep.20704 · Cited by 933
Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency
Knisely, A. S., Strautnieks, S. S., Meier, Y., Stieger, B., Byrne, J. A., Portmann, B. C., Bull, L. N., Pawlikowska, L., Bilezikçi, B., Özçay, F., et al. (2006) · Hepatology · doi:10.1002/hep.21287 · Cited by 377
4-Hydroxyphenylpyruvate dioxygenase
Moran, G. R. (2005) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.08.015 · Cited by 306
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations
Chinsky, J. M., Singh, R., Ficicioglu, C., van Karnebeek, C. D. M., Grompe, M., Mitchell, G., Waisbren, S. E., Gucsavas-Calikoglu, M., Wasserstein, M. P., Coakley, K., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.101 · Cited by 247
Recommendations for the management of tyrosinaemia type 1
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-8 · Cited by 227
Tyrosinemia: A Review
Russo, P., Mitchell, G. A., & Tanguay, R. M. (2001) · Pediatric and Developmental Pathology · doi:10.1007/s100240010146 · Cited by 226
Population history and its impact on medical genetics in Quebec
Laberge, A., Michaud, J. L., Richter, A. M., Lemyre, E., Lambert, M. A., Brais, B., & Mitchell, G. A. (2005) · Clinical Genetics · doi:10.1111/j.1399-0004.2005.00497.x · Cited by 201
A 3-year randomized therapeutic trial of nitisinone in alkaptonuria
Introne, W. J., Perry, M. B., Troendle, J. F., Tsilou, E. T., Kayser, M. A., Suwannarat, P., O'Brien, K. E., Bryant, J. C., Sachdev, V., Reynolds, J. C., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.04.016 · Cited by 201
Newborn Screening Fact Sheets
Kaye, C. I. (2006) · PEDIATRICS · doi:10.1542/peds.2006-1783 · Cited by 187
A journey of hope: lessons learned from studies on rare diseases and orphan drugs
Wästfelt, M., Fadeel, B., & Henter, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01666.x · Cited by 184
The genetic tyrosinemias
Scott, C. R. (2006) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30092 · Cited by 182
NTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
Masurel‐Paulet, A., Poggi‐Bach, J., Rolland, M. ‐., Bernard, O., Guffon, N., Dobbelaere, D., Sarles, J., de Baulny, H. O., & Touati, G. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0793-1 · Cited by 212
The pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167
Use of nitisinone in patients with alkaptonuria
Suwannarat, P., O’Brien, K., Perry, M. B., Sebring, N. G., Bernardini, I. M., Kaiser‐Kupfer, M. I., Rubin, B. I., Tsilou, E., Gerber, L. H., & Gahl, W. A. (2005) · Metabolism · doi:10.1016/j.metabol.2004.12.017 · Cited by 162
NONTRANSPLANT TREATMENT OF TYROSINEMIA
Holme, E., & Lindstedt, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70142-2 · Cited by 159
Self-citation
Nitisinone in the Treatment of Hereditary Tyrosinaemia Type 1
McKiernan, P. J. (2006) · Drugs · doi:10.2165/00003495-200666060-00002 · Cited by 151
Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec
Larochelle, J., Alvarez, F., Bussières, J.-F., Chevalier, I., Dallaire, L., Dubois, J., Faucher, F., Fenyves, D., Goodyer, P., Grenier, A., et al. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.05.022 · Cited by 137
Self-citation
Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice
Mayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0107-7 · Cited by 131
Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia
Pankowicz, F. P., Barzi, M., Legras, X. D., Hubert, L., Tian, M., Tomolonis, J., Ravishankar, M., Sun, Q., Yang, D., Borowiak, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12642 · Cited by 136
Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets
van Spronsen, F. J., van Rijn, M., Bekhof, J., Koch, R., & Smit, P. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.2.153 · Cited by 114
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases
Santucci, A., Bernardini, G., Braconi, D., Petricci, E., & Manetti, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01395 · Cited by 112
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Follow-Up Testing for Metabolic Disease Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry; Executive Summary
Dietzen, D. J., Rinaldo, P., Whitley, R. J., Rhead, W. J., Hannon, W. H., Garg, U. C., Lo, S. F., & Bennett, M. J. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.131300 · Cited by 104
Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots
Allard, P., Grenier, A., Korson, M. S., & Zytkovicz, T. H. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.07.006 · Cited by 99
Approaches to acute liver failure in children
Dhawan, A. K., Cheeseman, P., & Mieli‐Vergani, G. (2004) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2004.00292.x · Cited by 94
Acute Liver Failure in Children
Bucuvalas, J. C., Yazigi, N. A., & Squires, R. H. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2005.10.006 · Cited by 88
Long‐term therapy with NTBC and tyrosine‐restricted diet in a murine model of hereditary tyrosinemia type I
Al-Dhalimy, M., Overturf, K., Finegold, M., & Grompe, M. (2002) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3266 · Cited by 86
Diagnosis and early management of inborn errors of metabolism presenting around the time of birth1
Leonard, J. V., & Morris, A. A. M. (2005) · Acta Paediatrica · doi:10.1080/08035250500349413 · Cited by 85
The Cost-Effectiveness of Expanding Newborn Screening for up to 21 Inherited Metabolic Disorders Using Tandem Mass Spectrometry: Results from a Decision-Analytic Model
Cipriano, L. E., Rupar, C. A., & Zaric, G. S. (2007) · Value in Health · doi:10.1111/j.1524-4733.2006.00156.x · Cited by 82
Impaired Cognitive Functioning in Patients with Tyrosinemia Type I Receiving Nitisinone
Bendadi, F., de Koning, T. J., Visser, G., Prinsen, H. C. M. T., der Velden, M. G. M. D. S., Verhoeven‐Duif, N. M., Sinnema, G., van Spronsen, F. J., & van Hasselt, P. M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.10.001 · Cited by 81
Neurocognitive outcome in patients with hypertyrosinemia type I after long‐term treatment with NTBC
Thimm, E., Richter‐Werkle, R., Kamp, G., Molke, B., Herebian, D., Klee, D., Mayatepek, E., & Spiekerkoetter, U. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9394-5 · Cited by 79
Inhibition of Glutathione S-Transferase ζ and Tyrosine Metabolism by Dichloroacetate: A Potential Unifying Mechanism for Its Altered Biotransformation and Toxicity
Cornett, R., James, M. O., Henderson, G. N., Cheung, J., Shroads, A. L., & Stacpoole, P. W. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1287 · Cited by 74
Inborn errors of metabolism around time of birth
Leonard, J. V., & Morris, A. A. M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02591-5 · Cited by 73
Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1
Santra, S., & Baumann, U. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1229 · Cited by 68
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 66
Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia
Demers, S. I., Russo, P., Lettre, F., & Tanguay, R. M. (2003) · Human Pathology · doi:10.1016/s0046-8177(03)00406-4 · Cited by 67
Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
Das, A. M. (2017) · The Application of Clinical Genetics · doi:10.2147/tacg.s113310 · Cited by 70
Chronic liver disease in murine hereditary tyrosinemia type 1 induces resistance to cell death
Vogel, A., van den Berg, I. E. T., Al-Dhalimy, M., Groopman, J. D., Ou, C., Ryabinina, O. P., Iordanov, M. S., Finegold, M. J., & Grompe, M. (2004) · Hepatology · doi:10.1002/hep.20077 · Cited by 66
Tyrosinemia type I treated by NTBC: How does AFP predict liver cancer?
Koelink, C., van Hasselt, P. M., van der Ploeg, A., van den Heuvel‐Eibrink, M. M., Wijburg, F. A., Bijleveld, C. M. A., & van Spronsen, F. J. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.07.009 · Cited by 65
Outcome of tyrosinaemia type III
Ellaway, C. J., Holme, E., Standing, S., Preece, M. A., Green, A., Plöchl, E., Ugarte, M., Trefz, F. K., & Leonard, J. V. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1013936107064 · Cited by 65
Self-citation
Mutations in the 4-hydroxyphenylpyruvate dioxygenase gene ( HPD ) in patients with tyrosinemia type III
Rüetschi, U., Cerone, R., Pérez‐Cerdá, C., Schiaffino, M. C., Standing, S., Ugarte, M., & Holme, E. (2000) · Human Genetics · doi:10.1007/s004390000307 · Cited by 62
Self-citation
Newborn Screening for Hepatorenal Tyrosinemia: Tandem Mass Spectrometric Quantification of Succinylacetone
Sander, J., Janzen, N., Peter, M., Sander, S., Steuerwald, U., Holtkamp, U., Schwahn, B., Mayatepek, E., Trefz, F. K., & Das, A. M. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059790 · Cited by 62
Metabolic Liver Disease in Children
Hansen, K., & Horslen, S. P. (2008) · Liver Transplantation · doi:10.1002/lt.21470 · Cited by 61
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1
van Ginkel, W. G., Rodenburg, I. L., Harding, C. O., Hollak, C. E. M., Heiner-Fokkema, M. R., & van Spronsen, F. J. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00364-4 · Cited by 62
Neonatal Cholestasis
Lane, E. R., & Murray, K. F. (2017) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2017.01.006 · Cited by 56
Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I
Thimm, E., Herebian, D., Assmann, B., Klee, D., Mayatepek, E., & Spiekerkoetter, U. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.11.003 · Cited by 55
Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report
Grompe, M., Overturf, K., Al-Dhalimy, M., & Finegold, M. J. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005462804271 · Cited by 54
Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry
Hughes, A. T., Milan, A. M., Davison, A., Christensen, P. S., Ross, G. A., Gallagher, J. A., Dutton, J. J., & Ranganath, L. R. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215571969 · Cited by 51
Structural insights of 4-Hydrophenylpyruvate dioxygenase inhibition by structurally diverse small molecules
Dong, J., Dong, J., Yu, X., Yan, Y.-C., Nan, J.-X., He, B., Ye, B.-Q., Yang, W., Lin, H., & Yang, G. (2022) · Advanced Agrochem · doi:10.1016/j.aac.2022.10.002 · Cited by 52
Liver transplantation for hereditary tyrosinemia type I: Analysis of the UNOS database
Arnon, R., Annunziato, R. A., Miloh, T., Wasserstein, M., Sogawa, H., Wilson, M., Suchy, F. J., & Kerkar, N. N. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2011.01497.x · Cited by 52
Disorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Self-citation
The Pathogenesis of Hepatocellular Carcinoma
Kirstein, M. M., & Vogel, A. (2014) · Digestive Diseases · doi:10.1159/000360499 · Cited by 51
In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I
Manning, K., Al-Dhalimy, M., Finegold, M. J., & Grompe, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11928 · Cited by 50
Neonatal hepatitis syndrome
Roberts, E. A. (2003) · Seminars in Neonatology · doi:10.1016/s1084-2756(03)00093-9 · Cited by 50
Ophthalmic follow‐up of patients with tyrosinaemia type I on NTBC
Gissen, P., Preece, M. A., Willshaw, H. A., & McKiernan, P. J. (2003) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1024011110116 · Cited by 49
Metabolic liver disease in children
Hansen, K., & Horslen, S. P. (2008) · Liver Transplantation · doi:10.1002/lt.21520 · Cited by 49
Cardiomyopathy in tyrosinaemia type I is common but usually benign
Arora, N., Stumper, O., Wright, J., Kelly, D. A., & McKiernan, P. J. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0203-5 · Cited by 48
The Origin, Biology, and Therapeutic Potential of Facultative Adult Hepatic Progenitor Cells
Shin, S., & Kaestner, K. H. (2014) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/b978-0-12-416022-4.00010-x · Cited by 46
Clinical practice: NTBC therapy for tyrosinemia type 1: how much is enough?
El-Karaksy, H., Rashed, M., El-Sayed, R., El-Raziky, M., El-Koofy, N., El-Hawary, M., & Al-Dirbashi, O. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-009-1090-1 · Cited by 45
The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool
Milan, A. M., Hughes, A. T., Davison, A. S., Devine, J., Usher, J. L., Curtis, S., Khedr, M., Gallagher, J. A., & Ranganath, L. R. (2017) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563217691065 · Cited by 45
Liver Cancer in Tyrosinemia Type 1
van Ginkel, W. G., Pennings, J. P., & van Spronsen, F. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_9 · Cited by 45
HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1
Neto, J. S., Leite, K. R. M., Porta, A., da Fonseca, E. A., Feier, F. H., Pugliese, R. P. S., Miura, I. K., Chapchap, P., & Porta, G. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25094 · Cited by 44
Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
García, M. I., Alicia De la Parra, C., Arias, C., Arredondo, M., & Cabello, J. F. (2017) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2017.01.016 · Cited by 43
Corneal opacities associated with NTBC treatment
Ahmad, S., Teckman, J. H., & Lueder, G. T. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01532-5 · Cited by 43
Genetic and metabolic liver disease
Thompson, R. J., Portmann, B. C., & Roberts, E. A. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7020-3398-8.00004-0 · Cited by 43
Current Strategies for the Treatment of Hereditary Tyrosinemia Type I
Ashorn, M. H., Pitkänen, S. T., Salo, M. K., & Heikinheimo, M. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608010-00004 · Cited by 41
CRISPR/Cas9: at the cutting edge of hepatology
Pankowicz, F. P., Jarrett, K. E., Lagor, W. R., & Bissig, K. (2017) · Gut · doi:10.1136/gutjnl-2016-313565 · Cited by 43
Renal function in tyrosinaemia type I after liver transplantation: A long‐term follow‐up
Pierik, L. J. W. M., van Spronsen, F. J., Bijleveld, C. M. A., & van Dael, C. M. L. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-0059-0 · Cited by 40
Targeting glioma-initiating cells via the tyrosine metabolic pathway
Yamashita, D., Bernstock, J. D., Elsayed, G., Sadahiro, H., Mohyeldin, A., Chagoya, G., Ilyas, A., Mooney, J. H., Estévez-Ordoñez, D., Yamaguchi, S., et al. (2020) · Journal of neurosurgery · doi:10.3171/2019.11.jns192028 · Cited by 38
Splicing mutations, mainly IVS6-1(G>T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients
Arranz, J. A., Piñol, F., Kozák, L., Pérez‐Cerdá, C., Cormand, B., Ugarte, M., & Riudor, E. (2002) · Human Mutation · doi:10.1002/humu.10084 · Cited by 37
Spectrophotometric Microassay for δ-Aminolevulinate Dehydratase in Dried-Blood Spots as Confirmation for Hereditary Tyrosinemia Type I
Schulze, A., Frommhold, D., Hoffmann, G. F., & Mayatepek, E. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.8.1424 · Cited by 37
NTBC Treatment of the Pyomelanogenic Pseudomonas aeruginosa Clinical Isolate PA1111 Inhibits Pigment Production and Increases Sensitivity to Oxidative Stress
Ketelboeter, L. M., Potharla, V. Y., & Bardy, S. L. (2014) · Current Microbiology · doi:10.1007/s00284-014-0593-9 · Cited by 36
Extensive changes in liver gene expression induced by Hereditary Tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC)
Luijerink, M., Jacobs, S. M. M., van Beurden, E. A. C. M., Koornneef, L. P., Klomp, L. W. J., Berger, R., & van den Berg, I. E. T. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00433-1 · Cited by 36
Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies
Foster, J. R., Lund, G. A., Sapelnikova, S., Tyrrell, D. L., & Kneteman, N. M. (2013) · Xenobiotica · doi:10.3109/00498254.2013.867553 · Cited by 35
Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients
van Ginkel, W. G., Jahja, R., Huijbregts, S. C. J., & van Spronsen, F. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_10 · Cited by 34
Alkaptonuria – Many questions answered, further challenges beckon
Davison, A. S., Hughes, A., Milan, A. M., Sireau, N. T., Gallagher, J. A., & Ranganath, L. R. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219879957 · Cited by 36
New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure
Debray, D., Yousef, N., & Durand, P. (2006) · Pediatric Drugs · doi:10.2165/00148581-200608010-00001 · Cited by 35
Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah−/− knockout mice model
Orejuela, D., Jorquera, R., Bergeron, A., Finegold, M. J., & Tanguay, R. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.014 · Cited by 34
Hepatocellular carcinoma despite long‐term survival in chronic tyrosinaemia I
Kim, S. Z., Kupke, K. G., Ierardi-Curto, L. A., Holme, E., Greter, J., Tanguay, R. M., Poudrier, J., D’Astous, M., Lettre, F., Hahn, S. H., et al. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1026756501669 · Cited by 35
Self-citation
Reversible Keratopathy Due to Hypertyrosinaemia Following Intermittent Low-Dose Nitisinone in Alkaptonuria: A Case Report
Stewart, R. M. K., Briggs, M. C., Jarvis, J. C., Gallagher, J. A., & Ranganath, L. R. (2014) · JIMD Reports · doi:10.1007/8904_2014_307 · Cited by 34
Liver Transplantation for Metabolic Liver Diseases
Zhang, K. Y., Tung, B. Y., & Kowdley, K. V. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.04.002 · Cited by 34
Reversibility of cirrhotic regenerative liver nodules upon NTBC treatment in a child with tyrosinaemia type I
Crone, J., Möslinger, D., Bodamer, O., Schima, W., Huber, W., Holme, E., & Ipsiroglu, S. S. (2003) · Acta Paediatrica · doi:10.1111/j.1651-2227.2003.tb02518.x · Cited by 34
Self-citation
Single dose NTBC‐treatment of hereditary tyrosinemia type I
Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9450-9 · Cited by 33
Hereditary tyrosinemia type 1 in T urkey: Twenty year single‐center experience
Zeybek, A. Ç. A., Kıykım, E., Soyuçen, E., Cansever, M. Ş., Altay, S., Zübarioğlu, T., Erkan, T., & Aydın, A. (2014) · Pediatrics International · doi:10.1111/ped.12503 · Cited by 33
Liver tumors in children with metabolic disorders.
Schady, D. A., Roy, A., & Finegold, M. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.10.08 · Cited by 33
Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse
Lock, E. A., Gaskin, P., Ellis, M. K., Provan, W. M., Robinson, M., & Smith, L. L. (2000) · Toxicology · doi:10.1016/s0300-483x(99)00205-x · Cited by 33
Nitisinone for the treatment of hereditary tyrosinemia type I
McKiernan, P. J. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.800807 · Cited by 31
Monitoring tyrosinaemia type I: Blood spot test for nitisinone (NTBC)
Sander, J., Janzen, N., Terhardt, M., Sander, S., Gökcay, G., Demirkol, M., Ozer, I., Peter, M., & Das, A. M. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.09.027 · Cited by 32
Tyrosinemia Type 1: Metastatic Hepatoblastoma With a Favorable Outcome
Nobili, V., Jenkner, A., Francalanci, P., Castellano, A., Holme, E., Callea, F., & Dionisi‐Vici, C. (2010) · PEDIATRICS · doi:10.1542/peds.2009-1639 · Cited by 32
Self-citation
Spectroscopic and computational studies of NTBC bound to the non-heme iron enzyme (4-hydroxyphenyl)pyruvate dioxygenase: Active site contributions to drug inhibition
Neidig, M. L., Decker, A., Kavana, M., Moran, G. R., & Solomon, E. I. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.242 · Cited by 32
Indications for combined liver and kidney transplantation in children
Chava, S. P., Singh, B. B., Pal, S., Dhawan, A. K., & Heaton, N. D. (2009) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2008.01046.x · Cited by 32
Inborn Errors of Metabolism
Trahms, C. M. (2001) · Elsevier eBooks · doi:10.1016/b978-012193155-1/50016-7 · Cited by 31
Disorders of phenylalanine and tyrosine metabolism
Alsharhan, H., & Ficicioglu, C. H. (2020) · Translational Science of Rare Diseases · doi:10.3233/trd-200049 · Cited by 30
1H NMR, 13C NMR, and Computational DFT Studies of the Structure of 2-Acylcyclohexane-1,3-diones and Their Alkali Metal Salts in Solution
Szczeciński, P., Gryff‐Keller, A., & Molchanov, S. (2006) · The Journal of Organic Chemistry · doi:10.1021/jo060583g · Cited by 30
Hepatocellular Carcinoma in Tyrosinemia Type 1 Without Clear Increase of AFP
van Ginkel, W. G., Gouw, A., van der Jagt, E. J., de Jong, K. P., Verkade, H. J., & van Spronsen, F. J. (2015) · PEDIATRICS · doi:10.1542/peds.2014-1913 · Cited by 29
Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria
Khedr, M., Judd, S., Briggs, M. C., Hughes, A. T., Milan, A. M., Stewart, R. M. K., Lock, E. A., Gallagher, J. A., & Ranganath, L. R. (2017) · JIMD Reports · doi:10.1007/8904_2017_62 · Cited by 28
Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia
Wilson, C. J., Wyk, K. G. V., Leonard, J. V., & Clayton, P. T. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005666426079 · Cited by 29
Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1
Maiorana, A., Malamisura, M., Emma, F., Boenzi, S., Ciommo, V. M. D., & Dionisi‐Vici, C. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.07.021 · Cited by 29
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis
Sterkel, M., Haines, L. R., Casas-Sánchez, A., Adung’a, V. O., Vionette-Amaral, R. J., Quek, S., Rose, C., dos Santos, M. S., Escude, N. G., Ismail, H. M., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3000796 · Cited by 26
Pharmacological rescue of the 14CoS/14CoS mouse: hepatocyte apoptosis is likely caused by endogenous oxidative stress
Dieter, M. Z., Freshwater, S. L., Miller, M. L., Shertzer, H. G., Dalton, T. P., & Nebert, D. W. (2003) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(03)00273-9 · Cited by 27
Maternal and fetal tyrosinemia type I
Segarra, N. G., Roche, S., Imbard, A., Benoist, J., Grenèche, M. O., Spraul, A., & de Baulny, H. O. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9569-8 · Cited by 27

Authors: Holme, E., & Lindstedt, S.
Affiliations: Sahlgrenska University Hospital (SE)
Venue: Journal of Inherited Metabolic Disease
Publisher: Wiley
Published: 1998-08
Volume: 21
Issue: 5
Pages: 507-517
ISSN: 0141-8955 (ISSN-L)
1573-2665
DOI: 10.1023/a:1005410820201
OpenAlex: W1567009066
Cited by: 264
References: 17
Citations by year: 2026: 1 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 7 · 2020: 6 · 2019: 10 · 2018: 2 · 2017: 18 · 2016: 7 · 2015: 8 · 2014: 14 · 2013: 11 · 2012: 7
FWCI: 5.92
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Inherited Metabolic Disease (publishedVersion)
PubMed (publishedVersion)
Funders: Swedish Cancer Foundation
Vetenskapsrådet
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords: NTBC, tyrosine catabolism, hepatocellular carcinoma prevention, liver transplantation, succinylacetone, early treatment initiation, treatment response
MeSH terms: Amino Acid Metabolism, Inborn Errors, Animals, Clinical Trials as Topic, Cyclohexanones, Enzyme Inhibitors, Humans, Nitrobenzoates, Tyrosine, 4-Hydroxyphenylpyruvate Dioxygenase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks